Connect with us

Media & Technology

Livewire Ergogenics Inc (OTCMKTS: LVVV) Powerful Runner as Estrella River Farms Receives Approval to Operate its Commercial Cannabis Business

Published

on

Livewire Ergogenics Inc (OTCMKTS: LVVV) is making a powerful move up the charts after the Company reportred today Estrella River Farms receiving its official APPROVAL TO OPERATE a commercial cannabis business from the County of San Luis Obispo, and the State of California. LVVV is getting noticed by some pretty heavy hitter penny stock players. LVVV is quickly emerging as an investors favorite and is currently among the most actively searched and talked about stocks in small caps. LVVV is looking to blaze a path along the likes of Enzolytics or Tesoro and break out into a whole new dimension – Tesoro went to multi dollars – a break over $0.04 and its blue skies ahead.  

The Company is currently building out its Estrella Ranch headquarters in Paso Robles, California which recently received approval for its State license application for cannabis cultivation on historic Estrella Ranch in California. Estrella River Farms has received notification from CalCannabis Cultivation Licensing, a division of the California Department of Food and Agriculture that its State license application was approved for its location in Paso Robles California in the Central Coast of California. The Company’s large facility acreage and the business model it has developed allows itto consistently scale our cultivation areas to full capacity as dictated by the increasing demand for our products and in accordance with each additional permit issued. Currently state approval is pending and the Company estimates the facility could produce $50 million in annual revenue at full capacity. 

Livewire Ergogenics Inc (OTCMKTS: LVVV) is focused on acquiring, managing, and licensing specialized “closed loop” turnkey cannabis real estate locations of fully compliant and permitted turnkey facilities to produce cannabis-based products and services in California and the state-wide distribution of these products. This includes the development and licensing of high-quality organic cannabinoid-based products and services and the creation of the high-quality “Estrella Weedery” brand. LiveWire Ergogenics does not produce, sell, or distribute products that are in violation of the United States Controlled Substance Act.  

In late 2019 the Company acquired Estrella Ranch headquarters in Paso Robles, California to construct and operate the world’s first Estate Grown Weedery and to centralize all LiveWire corporate and affiliate operations on this large historic property located in the heart of California’s world-renown Central Coast Wine Country. LiveWire will begin the cultivation process immediately upon the imminent State approval to take full advantage of the vast outdoor acreage and many well-suited residential and commercial buildings, encompassing the initial Phase 1 of 150,000sf of canopy, multiple buildings, supported with ample power and sufficient water supply from multiple onsite wells. The Company’s large facility acreage and the business model we have developed allows us to consistently scale our cultivation areas to full capacity as dictated by the increasing demand for our products and in accordance with each additional permit issued. Currently state approval is pending and the Company estimates the facility could produce $50 million in annual revenue at full capacity. 

Recently the Company has accelerated the construction of all necessary infrastructure improvements to satisfy the legal and environmental requirements for the approval of our cannabis cultivation operations. While we have encountered an abundance of complex Local and State rules and regulations, we have been able to successfully comply with local ordinances and have received final approval for our land use permit from the County, with State application approval pending. 

Since the acquisition of the ranch property over one year ago, the Company has established a valuable and long-term relationship with its main operator QDG Agriculture, to handle the required buildouts, infrastructure improvements and cultivation on the Ranch. We have passed the necessary tests for final permit approval and together with our operator and cultivation partner with successful operations in Humboldt, California, have taken all required steps to begin cultivation instantly, once the State License has been issued. On the production level, our cultivation partner has taken precautionary actions that will allow us to significantly shorten the timeline form the start of cultivation to first harvest. 

To Find out the inside Scoop on LVVV Subscribe to Microcapdaily.com Right Now by entering your Email in the box below

LVVV

 

On June 1 LVVV affiliate company Estrella River Farms received approval for its State license application for cannabis cultivation on historic Estrella Ranch in California.Estrella River Farms has received notification from CalCannabis Cultivation Licensing, a division of the California Department of Food and Agriculture that its State license application was approved for its location in Paso Robles California in the Central Coast of California. 

Bill Hodson, CEO of LiveWire and Managing Member of Estrella River Farms states, “Today, we are pleased to announce that ERF received approval for its initial acreage of outdoor cannabis cultivation and officially creates the world’s first Estate Grown Weedery ™ – the cultivation of organically grown, hand-crafted cannabis on a family style farm. This rigorous process took about 20 months to complete and is a major milestone in the execution of our long-term business plan and will allow us to accelerate the implementation of our unique and sustainable business model. Estrella River Farms is now at what I consider, the finish-start line and will have plants in the ground immediately following the County’s final walk-through inspection. As the legal environment continues to evolve, ERF will be in an ideal position to easily scale up cultivation to maximum capacity of the total available acreage, providing growth potential for years to come. The Company has already established multiple relationships with large distributors to enter into supply agreements, assuring immediate utilization of several well-established distribution channels. The application and compliance process is complex and time consuming, but the staff at San Luis Obispo County has been great to work with, especially through the challenges of this past year’s pandemic. We assembled a great team of consultants with in-depth knowledge of extensive local water conservation, endangered species and numerous zoning laws necessary to navigate the requirements set forth by the County. We also have the added benefit of being guided by the most knowledgeable cannabis attorney in the State to interpret and comply with all local and State regulations. Estrella Ranch was previously owned by the King of Morocco and later by the eldest grandson of William Randolph Hearst and is now considered the crown jewel of California cannabis properties, located in the heart of the Central Coast wine country – ideal for growing premium organic outdoor flower. The goal is for the crop and its branding to comply with, and be protected by, the CDFA’s Cannabis Appellations Program when their requirements are finalized.

 

For More on LVVV Subscribe Right Now!

Livewire Ergogenics Inc (OTCMKTS: LVVV) is making a powerful move up the charts after the Company reportred today Estrella River Farms receiving its official APPROVAL TO OPERATE a commercial cannabis business from the County of San Luis Obispo, and the State of California. LVVV is getting noticed by some pretty heavy hitter penny stock players. LVVV is quickly emerging as an investors favorite and is currently among the most actively searched and talked about stocks in small caps. LVVV is looking to blaze a path along the likes of Enzolytics or Tesoro and break out into a whole new dimension – Tesoro went to multi dollars – a break over $0.04 and its blue skies ahead.  The Company is currently building out its Estrella Ranch headquarters in Paso Robles, California which recently received approval for its State license application for cannabis cultivation on historic Estrella Ranch in California. Estrella River Farms has received notification from CalCannabis Cultivation Licensing, a division of the California Department of Food and Agriculture that its State license application was approved for its location in Paso Robles California in the Central Coast of California. The Company’s large facility acreage and the business model it has developed allows itto consistently scale our cultivation areas to full capacity as dictated by the increasing demand for our products and in accordance with each additional permit issued. Currently state approval is pending and the Company estimates the facility could produce $50 million in annual revenue at full capacity. We will be updating on LVVV when more details emerge so make sure you are subscribed to Microcapdaily so you know what’s going on with LVVV.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: we hold no position in LVVV either long or short and we have not been compensated for this article.

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Featured

LAVA Therapeutics (NASDAQ: LVTX) Gammabody™ Platform Gains Momentum

Published

on

LAVA Therapeutics N.V. (NASDAQ: LVTX) shares soared 106% as the company announced that Janssen Biotech, Inc. chose a lead candidate.

LAVA Therapeutics N.V. (NASDAQ: LVTX) shares soared 106% as the company announced that Janssen Biotech, Inc., a part of the Janssen Pharmaceutical Companies of Johnson & Johnson, chose a lead candidate aimed at an undisclosed tumor-associated antigen for further development towards clinical settings.

GAMMABODY™ PLATFORM

LAVA primarily focuses on revolutionizing cancer therapy by developing its Gammabody™ platform. This platform enables them to create bispecific gamma delta T cell engagers that can activate a specific subset of gamma-delta T cells called Vγ9Vδ2 (Vgamma9 Vdelta2) T cells. By utilizing this approach, they aim to enhance the natural recognition of tumors, guide Vγ9Vδ2 T cells to target the tumor cells directly and trigger a cascade of immune responses.

To Discover the Inside Scoop on LVTX, Subscribe to Microcapdaily.com Right Now by entering your Email in the box below.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

What sets their Gammabody™ drug candidates apart is their exceptional performance and safety profiles observed in preclinical studies. Compared to other bispecific T cell engager approaches, their candidates have demonstrated superior efficacy and preferred targeting tumor cells. This targeted approach has the potential to minimize toxicity in healthy tissues.

In May 2020, LAVA entered into a research collaboration and license agreement with Janssen, a subsidiary of the Janssen Pharmaceutical Companies of Johnson & Johnson. This collaboration aimed to discover and develop novel bispecific antibody-based gamma delta T cell engagers for cancer treatment. The agreement was facilitated by Johnson & Johnson Innovation, emphasizing their commitment to fostering innovation in the field.

As part of the collaboration, LAVA had the opportunity to receive potential milestone payments and royalties based on the successful development, regulatory approvals, and commercialization of the candidates. This incentivized LAVA to actively pursue the discovery and advancement of promising lead candidates. 

The collaboration represents a remarkable milestone many early-stage biotech companies aspire to achieve. Partnering with a program brings numerous benefits, including reduced risk of dilution through milestone payments as the trials advance and streamlined commercialization once the product receives approval.

Under the terms of the agreement, Janssen will assume responsibility for the selected candidate’s future clinical development, manufacturing, and commercialization. This includes bearing the costs and expenses associated with these activities.

Stephen Hurly, LAVA Therapeutics’s president and chief executive officer, expressed satisfaction with Janssen’s selection of a lead candidate for clinical studies. He emphasized LAVA’s pioneering role in developing gamma-delta bispecific antibodies through their proprietary Gammabody platform. This platform and LAVA’s extensive expertise in bispecific antibody development position them at the forefront of advancing novel therapies for cancer patients.

In summary, LAVA Therapeutics’ collaboration with Janssen has reached a significant milestone in selecting a lead candidate for further development toward clinical studies. This progress underscores LAVA’s dedication to leveraging its Gammabody platform and expertise in bispecific antibody development to revolutionize cancer treatment.

We will update you on LVTX when more details emerge, so make sure you are subscribed to Microcapdaily to know what’s happening in the markets!

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.

Continue Reading

Featured

Onfolio Holdings (NASDAQ: ONFO) Unleashing the Power of AI

Published

on

Onfolio Holdings Inc (NASDAQ: ONFO), a technology services company, has recently introduced an advanced generative AI search function for its subsidiary, MightyDeals.com.

Onfolio Holdings Inc (NASDAQ: ONFO), a technology services company, has recently introduced an advanced generative AI search function for its subsidiary, MightyDeals.com. The implementation of this innovative AI tool, powered by chatGPT-style Large Language Models (LLMs), has resulted in a surge of 105% in the company’s stock price and sparked tons of investor interest. The company has a 3.28M float and, at the time of writing, has traded 20x that amount, with a colossal 60M shares exchanging hands.

Revolutionizing User Experience and Driving Stock Surge

With the integration of AI search on MightyDeals.com, customers can now use natural language to describe the products they seek, simplifying the buying process. The AI tool utilizes contextual understanding and description analysis of hundreds of active deals to generate instant search results based on users’ queries. By enhancing the user experience, Onfolio Holdings anticipates increased user return rates, higher site interaction rates, and elevated revenues for MightyDeals.com. This groundbreaking development has attracted positive attention, significantly increasing Onfolio Holdings’ stock price.

To Discover the Inside Scoop on ONFO, Subscribe to Microcapdaily.com Right Now by entering your Email in the box below.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Evaluating Financial Performance

While the stock surge indicates investor enthusiasm, assessing Onfolio Holdings’ financial performance is crucial for comprehensive investment analysis. The positive earnings growth of +44.44% and revenue growth of +22.74% contribute to the company’s optimistic outlook. However, investors should be cautious of the negative net profit margin of -190.75% and the lack of available price/book ratio data. Monitoring the company’s financial performance leading up to the next reporting date on August 30, 2023, is advised to understand its profitability and overall stability better.

Investment Outlook and Future Prospects

Considering the stock surge and optimistic price forecasts, Onfolio Holdings has promising prospects. Analysts offer a median target price of $3.00 for the company’s stock, signaling an expectation of significant growth within the next 12 months. However, it is essential to note that Onfolio Holdings operates at a loss. Investors should thoroughly evaluate the company’s long-term growth potential and weigh the potential returns against the inherent risks before making investment decisions.

About MightyDeals.com

Mighty Deals is a free daily deals website aimed at creative professionals focusing on products and services for web designers and developers. The site offers fantastic deals on quality fonts, templates, apps, add-ons, plug-ins, ebooks, icons, and more. The site provides discounts on packages which usually range between 50%-97% off but are only available for a limited time. MightyDeals.com boasts an exceptional return rate from its users and is one of Onfolio Holdings’ highest revenue-generating subsidiaries.

About Onfolio Holdings Inc.

Onfolio acquires and manages a diversified portfolio of online businesses across a broad range of verticals, each with a niche content focus and brand identity. Onfolio acquires firms that meet its investment criteria, being that such businesses operate in sectors with long-term growth opportunities, have positive and stable cash flows, face minimal threats of technological or competitive obsolescence, and can be managed by our existing team or have strong management teams largely in place. The Company excels at finding acquisition opportunities where the seller has not fully optimized their business. Onfolio’s experience and skillset allow it to add increased value to these existing businesses.

Conclusion

Onfolio Holdings’ introduction of the generative AI search function for MightyDeals.com has increased the company’s stock price, reflecting the market’s positive response to this innovative technology. The enhanced user experience and the potential for increased revenues have positioned Onfolio Holdings as a leader in the tech industry. However, investors must carefully consider the company’s financial performance and evaluate its long-term growth potential before making investment decisions. Monitoring the company’s performance to the next reporting date will provide valuable insights into its financial health and stability.

We will update you on ONFO when more details emerge, so make sure you are subscribed to Microcapdaily to know what’s happening in the markets!

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.

Image by James from Pixabay

Continue Reading

Featured

Enveric Biosciences (NASDAQ: ENVB) Pioneering the Future of Anxiety Disorder Treatment

Published

on

Enveric Biosciences, Inc. (NASDAQ: ENVB) shares surged 78% this morning upon approval of some fantastic news.

Enveric Biosciences, Inc. (NASDAQ: ENVB) shares surged 78% this morning upon approval of some fantastic news. The United States Patent and Trademark Office has granted them a notice of allowance for their patent application concerning a groundbreaking chemical compound called EB-373. This compound is being developed to address the treatment of anxiety disorders.

The forthcoming patent, titled “C4-Carbonothioate-Substituted Tryptamine Derivatives and Methods of Using,” encompasses claims for the composition of matter of a family of revolutionary prodrug derivatives of psilocin. Enveric’s lead product candidate, EB-373, stands out among these derivatives. A Notice of Allowance signifies that the USPTO has determined that a patent should be granted based on the submitted application.

To Discover the Inside Scoop on ENVB, Subscribe to Microcapdaily.com Right Now by entering your Email in the box below.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Enveric’s commitment to innovation extends beyond EB-373. They have also submitted additional patent applications to the USPTO, exploring psilocin prodrugs with unique crystalline molecular structures. Moreover, they have taken proactive steps to pursue global coverage of the EVM201 and EVM301 Series through companion Patent Cooperation Treaty and non-US national patent applications. Encouragingly, positive International Search Reports and written opinions have been received under the Patent Cooperation Treaty for most of these applications.

Joseph Tucker, Ph.D., Enveric’s director and CEO, underlined the significance of the USPTO’s favorable decision concerning their lead candidate, EB-373. He highlighted the innovative designs of their psilocin prodrugs within the EVM201 series, differentiating them from conventional counterparts like psilocybin. These novel designs hold the potential to deliver more rapid therapeutic effects, precise control, and reduced gastrointestinal side effects. Tucker emphasized that securing a robust intellectual property portfolio for their new chemical entity prodrugs is pivotal to Enveric’s value proposition and integral to their business strategy of developing cutting-edge small-molecule therapeutics to address mental health disorders.

We will update you on ENVB when more details emerge, so make sure you are subscribed to Microcapdaily to know what’s happening in the markets!

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.

Image by Gino Crescoli from Pixabay

Continue Reading

Trending

© All rights reserved.

Sign up now for our 100% FREE Penny Stock Newsletter

Privacy Policy. we will never share your email with anyone.